All In Biotech

BLA 761358 · Celltrion

Zymfentra

Infliximab-Dyyb · Injection

Last checked: Nov 20, 2026Latest source record: Feb 22, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Oct 20, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

379

125 Phase 3, 45 recruiting

FAERS reports

3,446

2,649 serious, 93 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as hitoplasmosis) and infections due to ohter opportunistic pathogens. (5.1) Discontinue ZYMFENTRA if a patient develops a serious infection or sepsis. (5.1) Perform test for latent TB; if positive, start treatment for TB prior to starting ZYMFENTRA. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. (5.1) Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab products. (5.2) Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients...

What it is approved for

From the label in effect Aug 18, 2026.

ZYMFENTRA is a tumor necrosis factor (TNF) blocker indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. ( 1 ) moderately to severely active Crohn’s disease following with an infliximab products administered intraneously. ( 1 ) ZYMFENTRA is indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. moderately to severely active Crohn's disease following treatment with an infliximab product administered intravetnously.

Mechanism: Infliximab-dyyb neutralize the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms of TNFα and inhibit binding of TNFα with its receptors. Infliximab-dyyb has shown biological activities, such as TNFα neutralization activity and TNFα binding affinities, complement 1q (C1q) binding affinity and crystallizable fragment (Fc) receptor binding affinities in a wide variety of in vitro bioasays. The relationship of these biological response markers to the mechanism(s) by which infliximab-dyyb exerts its clinical effects is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ZYMFENTRA · INFLIXIMAB-DYYB 120MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Infliximab" as an intervention, any sponsor and status, largest first.

All 379 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • inappropriate schedule of product administration991
  • off label use908
  • intentional dose omission840
  • product dose omission issue448
  • overdose320
  • suspected off label use311
  • weight decreased306
  • weight increased306
  • therapy interrupted294
  • arthralgia288
  • fatigue286
  • condition aggravated272

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20172
201812
20197
20209
202125
202259
2023153
2024382
2025882
20261,915

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zymfentra (Infliximab-Dyyb)

2024 spending

$222K

Beneficiaries

15

39 claims

Per beneficiary

$14,802

$2,741.20 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$222,037

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,993 on PubMed

Sponsor: Celltrion

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.